enGenes Biotech presents continuous plasmid DNA manufacturing at MSS2026 in Bled

Vienna, Austria: – Recombinant proteins and plasmid DNA specialist CDMO enGenes Biotech is heading to Bled, Slovenia, to present peer-reviewed data on continuous plasmid DNA (pDNA) manufacturing at the next-gen bioManufacturing & Delivery Science Symposium (MSS2026), running 14–16 September 2026 as a hybrid, onsite and online event.

Dr Juergen Mairhofer, CEO and co-founder of enGenes, will deliver a presentation in the symposium’s “Nucleic Acids and LNPs” stream, part of the “Next Generation Manufacturing Platforms” session, on Monday 14 September.

A single continuous line, from fermentation to purified plasmid

Dr Mairhofer’s talk, “iCAP: Integrated Continuous and Automated Platform for Plasmid Production”, runs from 16:10 to 17:00 in Hall F. It sets out how enGenes has combined a growth-decoupled E. coli host strain and fermentation process, inline alkaline lysis optimised with a mechanistic model, and monolithic chromatography into a single continuous line, monitored in real time.

Most plasmid DNA is still produced in batch mode, where yields are low and much of the eventual cost of goods is locked in as early as the fermentation step

Part of the dataset was developed with partners Sartorius BIA Separations, BOKU University Vienna, Novasign and Qubicon, and is published open access as Korn et al., Biochemical Engineering Journal 235 (2026) 110345.

Meeting the people who build and buy pDNA processes

Plasmid DNA is the starting material for mRNA vaccines, AAV and lentiviral vectors, and DNA vaccines, and MSS2026 is one of the few European meetings where upstream, downstream and analytical experts for nucleic acids sit in the same room. enGenes is using the symposium to meet mRNA, AAV, lentivirus and DNA vaccine manufacturers who need high-yield pDNA and would rather run the process in-house than continue buying material, as well as to identify potential licensees and partners for its E. coli platforms and buyers for its wider product portfolio and services.

Alongside iCAP, enGenes will discuss its eXpress™ growth-decoupled E. coli expression platform for recombinant proteins, its recombinant Protein A affinity ligands for resin and membrane manufacturers seeking a European supply source, and eXrase™, its recombinant endonuclease for nucleic acid removal in bioprocessing. The iCAP technology itself is offered as a licence package, combining the host strain, process know-how, pre-blended media and support, for companies that want to produce their own plasmid DNA rather than buy it in.

Dr Mairhofer commented: “Yield is what decides the cost of goods, but it’s rarely published by service providers. We think companies should be able to know and run a high-titre process themselves, and that process needs to be transferable into GMP. That’s the case we’re making at MSS2026, backed by data now published in the Biochemical Engineering Journal.”

About enGenes Biotech

enGenes Biotech GmbH (enGenes) is a contract research, development and manufacturing company that provides leading-edge technologies and production services focused on recombinant proteins in bacteria. The company’s mission is to provide cost-effective and scalable production of recombinant proteins at a fraction of the current cost, allied to a vision of developing a world-class portfolio of cutting-edge protein production technologies, relevant to a broad spectrum of application fields.

enGenes has developed advanced technologies to drive more cost-effective recombinant protein production processes, including its proprietary enGenes-e^Xpress™ E. coli platform that achieves outstanding yields of soluble and active recombinant protein. enGenes- e^Xpress™ has been successfully applied for the manufacturing of enzymes and biopharmaceutical products that failed to give economically feasible yields in a conventional expression host.

enGenes Biotech offers development and manufacturing services tailored to the needs of pharmaceutical and industrial biotech companies. The services include expression strain and vector development, fermentation process development and optimization, downstream process development, production of purified protein, technology transfer and scale-up support with technology out-licensing and co-development opportunities.

Find out more at: https://www.engenes.cc

About MSS2026

The next-gen bioManufacturing & Delivery Science Symposium (MSS2026) takes place in Bled, Slovenia, from 14–16 September 2026, with an opening session on the evening of 13 September, and is run as a hybrid event, onsite and online. The symposium is organised by MSS Biotech Events, with a Scientific and Organizing Committee chaired by Ales Strancar.

More information is available at: https://mss-biotechevents.org

Resources

Read the open-access publication: Korn et al., “Enabling continuous plasmid DNA production: model-based optimization of inline alkaline lysis“.
Download the enGenes pDNA whitepaper Enhanced plasmid DNA manufacturing using enGenes eXcess technology and an optimized downstream platform.
View the MSS2026 agenda.
Contact enGenes to set up meeting at MSS2026.